Oppenheimer Sees Strong Upside for Abbott (ABT) with Volt System and Diabetes Innovation

By Yahoo! Finance   |   2 weeks ago
Oppenheimer Sees Strong Upside for Abbott (ABT) with Volt System and Diabetes Innovation

Abbott Laboratories (NYSE:ABT) is favored for early retirement portfolios with a $140 price target by Oppenheimer. The company's Volt system and glucose-ketone monitoring technology have shown promise, with potential growth catalysts ahead.

Read More

Did you find this insightful?